Table 4 Agreement of INNOTEST and Lumipulse biomarker and ratio results on the training cohort
INNOTEST | Lumipulse | OPA | |
|---|---|---|---|
Negative | Positive | ||
Aβ42 | |||
Negative | 41 (34.2%) | 4 (3.3%) | 114 (95.0%) |
Positive | 2 (1.7%) | 73 (60.8%) | |
t-Tau | |||
Negative | 40 (33.3%) | 0 (0.0%) | 116 (96.7%) |
Positive | 4 (3.3%) | 76 (63.3%) | |
p-Tau | |||
Negative | 34 (28.3%) | 7 (5.8%) | 105 (87.5%) |
Positive | 8 (6.7%) | 71 (59.2%) | |
Aβ42/Aβ40 | |||
Negative | 33 (27.5%) | 10 (8.3%) | 105 (87.5%) |
Positive | 5 (4.2%) | 72 (60.0%) | |
Aβ42/t-Tau | |||
Negative | 39 (32.5%) | 1 (0.8%) | 117 (97.5%) |
Positive | 2 (1.7%) | 78 (65.0%) | |
Aβ42/p-Tau | |||
Negative | 38 (31.7%) | 5 (4.2%) | 113 (94.2%) |
Positive | 2 (1.7%) | 75 (62.5%) | |
CSF-AD profile | |||
Negative | 34 (28.3%) | 8 (6.7%) | 108 (90.0%) |
Positive | 4 (3.3%) | 74 (61.7%) | |